(Q34761260)

4 August 2017

1 reference

title

The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil (English)

1 reference

dihydropyrimidine dehydrogenase deficiency

4 August 2017

main subject

0 references

1 reference

Bridget A Robinson

3

0 references

Evan Begg

series ordinal

2

object named as

Evan J Begg

1 reference

4 August 2017

Sharon J Gardiner

1

1 reference

4 August 2017

publication date

1 January 2002

1 reference

4 August 2017

published in

Toxicological Reviews

1 reference

4 August 2017

volume

21

1 reference

4 August 2017

issue

1-2

1 reference

4 August 2017

page(s)

1-16

1 reference

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Clinical pharmacology of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Fluorouracil: biochemistry and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Metabolism of pyrimidine analogues and their nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

A new case of dihydropyrimidine dehydrogenase deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Clinical variability in three Danish patients with dihydropyrimidine dehydrogenase deficiency all homozygous for the same mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Hepatic drug metabolism and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Cardiotoxicity of the antiproliferative compound fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

"Organic brain syndrome" secondary to 5-fluorouracil toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Fluorouracil-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Myocardial ischemia induced by topical use of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Circulating drug levels in patients presenting cardiotoxicity to 5-FU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Coronary vasospasm as a cause of effort-related myocardial ischemia during low-dose chronic continuous infusion of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

5-Fluorouracil by protracted venous infusion. A review of current progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Lack of correlation between phenotype and genotype for the polymorphically expressed dihydropyrimidine dehydrogenase in a family of Pakistani origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Dihydropyrimidine dehydrogenase deficiency: a novel mutation and expression of missense mutations in E. coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Oral fluoropyrimidines: a closer look at their toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Clinical pharmacokinetics of capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

Fluorouracil cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256180

21 January 2018

Identifiers

DOI

10.1007/BF03256180

1 reference

4 August 2017

1 reference